CN112075504A - Infant formula milk powder for enhancing immunity - Google Patents
Infant formula milk powder for enhancing immunity Download PDFInfo
- Publication number
- CN112075504A CN112075504A CN202011064571.3A CN202011064571A CN112075504A CN 112075504 A CN112075504 A CN 112075504A CN 202011064571 A CN202011064571 A CN 202011064571A CN 112075504 A CN112075504 A CN 112075504A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- infant formula
- milk powder
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 53
- 235000013336 milk Nutrition 0.000 title claims abstract description 37
- 239000008267 milk Substances 0.000 title claims abstract description 37
- 210000004080 milk Anatomy 0.000 title claims abstract description 37
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 31
- 230000036039 immunity Effects 0.000 title claims abstract description 30
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 17
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 22
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 22
- 102000004264 Osteopontin Human genes 0.000 claims abstract description 22
- 108010081689 Osteopontin Proteins 0.000 claims abstract description 22
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 22
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 22
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 22
- 241000186315 Lactobacillus paracasei N1115 Species 0.000 claims abstract description 19
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 12
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 12
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000005862 Whey Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 235000020247 cow milk Nutrition 0.000 claims abstract description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 5
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 5
- 239000000944 linseed oil Substances 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 235000021119 whey protein Nutrition 0.000 claims abstract description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 4
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 4
- 229960003178 choline chloride Drugs 0.000 claims abstract description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000006071 cream Substances 0.000 claims abstract description 4
- 235000021323 fish oil Nutrition 0.000 claims abstract description 4
- 239000008101 lactose Substances 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 4
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 4
- 239000003549 soybean oil Substances 0.000 claims abstract description 4
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- -1 compound vitamin Chemical class 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 13
- 210000004251 human milk Anatomy 0.000 abstract description 13
- 238000011161 development Methods 0.000 abstract description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 229960003563 calcium carbonate Drugs 0.000 abstract description 2
- 235000010216 calcium carbonate Nutrition 0.000 abstract description 2
- 229940067631 phospholipid Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241001591005 Siga Species 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940093932 potassium hydroxide Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of food, and particularly discloses infant formula milk powder for enhancing immunity, which comprises raw materials for preparing effective components of cow milk, lactose, desalted whey powder subjected to partial enzymolysis, 1, 3-dioleate-2-palmitic acid triglyceride, soybean oil, concentrated whey protein powder, linseed oil, galacto-oligosaccharide, anhydrous cream, fructo-oligosaccharide, phospholipid, arachidonic acid powder, compound mineral substances, fish oil powder, compound vitamins, lactoferrin, calcium carbonate, osteopontin, potassium hydroxide, choline chloride, nucleotide and lactobacillus paracasei N1115. The composition of the infant formula milk powder for enhancing the immunity provided by the invention is close to breast milk, so that the nutrition required by the growth and development of infants is ensured, the immunity of the infants is enhanced, and the infection and illness of newborns are prevented. The invention is suitable for infants of 0-6 months, in particular to newborns with low resistance.
Description
Technical Field
The invention belongs to the field of food, and relates to milk powder, in particular to infant formula milk powder for enhancing immunity.
Background
Breast milk provides the ideal nutritional component for the newborn, and is the most important source of nutrients and bioactive components for the growth and development of infants and for protection against external bacterial and viral insults before the infants can themselves ingest and digest other foods. The World Health Organization (WHO) recommends that the infant is fed with pure breast milk within the first 6 months after birth and the breast milk is fed for 2 years or more, however, the breast milk feeding rate in China is still low at present, and the infant formula milk powder is particularly important as a breast milk substitute in the infant group lacking the breast milk feeding.
The composition of breast milk is extremely complex, besides protein, fat, carbohydrate, mineral, vitamin and water, a large amount of bioactive components for enhancing the immunity of infants exist, the content of lactoferrin in the breast milk is 90-800 mg/100mL, and the content of osteopontin is 13.5-328.1 mg/100 mL. Compared with breast milk, the ratio of various nutrient components in cow milk is greatly different, wherein the variety of bioactive components is less and the content is low, the lactoferrin content in cow milk is 2-500 mg/100mL, and the osteopontin content is 1.8 mg/100 mL. Therefore, the content of active protein in cow milk is far lower than that of breast milk, so that the infants eating the common cow milk powder are more easily infected by external pathogenic microorganisms to become sick in the early growth stage.
Disclosure of Invention
The invention aims to provide infant formula milk powder for enhancing immunity aiming at infants so as to enhance the immunity of artificially fed infants.
In order to achieve the purpose, the invention adopts the following technical scheme:
an infant formula milk powder for enhancing immunity comprises, by weight, 60-75 parts of cow milk, 8-12 parts of lactose, 5-8 parts of partially-hydrolyzed desalted whey powder, 3-6 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 2-4 parts of soybean oil, 1-3 parts of concentrated whey protein powder, 1-3 parts of linseed oil, 0.5-1.5 parts of galacto-oligosaccharide, 0.4-1 part of anhydrous cream, 0.1-0.5 part of fructo-oligosaccharide, 0.1-0.3 part of phospholipid, 0.1-0.3 part of peanut powder, 0.1-0.3 part of compound mineral, 0.1-0.2 part of fish oil powder, 0.1-0.2 part of compound vitamin, 0.1-0.2 part of lactoferrin, 0.05-0.1 part of calcium carbonate, 0.025-0.05 part of osteopontin, 0.025 part of calcium carbonate, 0.01-0.05 part of potassium hydroxide, 0.01-0.05 part of choline chloride, 0.01-0.05 part of nucleotide and 0.01-0.05 part of lactobacillus paracasei N1115.
As a limitation: the raw materials for preparing the effective components also comprise 0.005-0.01 part of ganglioside by weight.
As a further limitation: the degree of enzymatic hydrolysis of the partially enzymatically hydrolyzed desalted whey powder was 10%.
As yet a further limitation: the content of Lactobacillus paracasei N1115 is 1 × 1011-1×1012 CFU/g。
As a further limitation: the adding proportion of the lactoferrin to the osteopontin in the raw materials for preparing the effective components is 4:1 in parts by weight.
The lactobacillus paracasei N1115 related in the formula is separated and screened from traditional fermented milk products of Mongolia in China, has been preserved in the strain preservation center of the institute of microbiology of Chinese academy of sciences in 3 months of 2011, and has the preservation number of CGMCC No. 4691. The gene sequence of lactobacillus paracasei N1115 has been disclosed in chinese patent application No. 2011103570588 entitled "lactobacillus casei N1115, its immunomodulatory effect and use".
Due to the adoption of the scheme, compared with the prior art, the invention has the beneficial effects that:
(1) the lactoferrin, the osteopontin and the lactobacillus paracasei N1115 are added into the infant formula milk powder for enhancing the immunity, and the lactoferrin, the osteopontin and the lactobacillus paracasei N1115 are synergistic, so that the immunity can be enhanced, and the morbidity of a newborn is reduced; in addition, the linseed oil and the 1, 3-dioleic acid-2-palmitic acid triglyceride are added into the milk powder, so that the contents of alpha-linolenic acid and sn-2-palmitic acid are improved, the composition of the milk powder is closer to that of fatty acid in breast milk, the nutrition required by the growth and development of infants is ensured, and the healthy development of intestinal tracts is promoted;
(2) the infant formula milk powder for enhancing immunity provided by the invention is added with two prebiotics, namely fructo-oligosaccharide and galacto-oligosaccharide, so that the proliferation of bifidobacteria in intestinal tracts is promoted, the intestinal development and maturity of infants are promoted, and the immune function of infants is enhanced, so that the infants are protected from being infected and diseased;
(3) the ganglioside is added into the infant formula milk powder for enhancing the immunity, so that the intestinal flora of the newborn is adjusted, the development of the intestinal immune system of the newborn is promoted, and the early infection of the infant is prevented;
(4) the infant formula milk powder for enhancing immunity provided by the invention is added with the partially-enzymolyzed desalted whey powder, so that main protein allergens in the milk powder can be effectively destroyed, the total IgE level in serum is reduced, and the allergenicity of whey protein is reduced.
In conclusion, the composition of the infant formula milk powder for enhancing immunity provided by the invention is close to breast milk, so that nutrition required by growth and development of infants is ensured, the immunity of newborns is enhanced, and the infection and illness of the newborns are prevented.
The invention is suitable for infants of 0-6 months, in particular to newborns with low resistance.
Drawings
The invention is described in further detail below with reference to the figures and the embodiments.
FIG. 1 is a graph showing the results of varying concentrations of IL-18 secretion in combination with lactoferrin, osteopontin and Lactobacillus paracasei N1115 in example 7 of the present invention;
FIG. 2 is a graph showing the results of the weight change of a mouse in example 8 of the present invention;
FIG. 3 is a graph showing the results of measurement of mouse fecal sIgA according to example 8 of the present invention.
Detailed Description
The present invention is further described with reference to the following examples, but it should be understood by those skilled in the art that the present invention is not limited to the following examples, and any modifications and variations based on the specific examples of the present invention are within the scope of the claims of the present invention.
Examples 1-6 Immunity-enhancing infant formula milk powder
Examples 1-6 are a method of preparing an infant formula milk powder for enhancing immunity, respectively, the raw material composition of which is shown in table 1, and the process parameters for preparing the milk powder are shown in table 2.
The preparation method comprises the following steps:
s1, standardizing raw milk, separating impurities, pasteurizing at 70-75 ℃ for 15-18S to obtain milk, adding lactose, desalted whey powder with partial enzymolysis degree of 10%, 1, 3-dioleate-2-palmitic acid triglyceride, soybean oil, concentrated whey protein powder, linseed oil, galacto-oligosaccharide, anhydrous cream, fructo-oligosaccharide, phospholipid, compound mineral substances, compound vitamins, calcium carbonate, potassium hydroxide and choline chloride into the milk, stirring and mixing uniformly, and dissolving sufficiently to obtain a material A;
s2, preheating the material A to 58-62 ℃, homogenizing under the pressure of 15-18MPa, and then heating to 85-95 ℃ for sterilization for 20-30S to obtain a material B;
s3, evaporating and concentrating the material B through a four-effect falling film to prepare concentrated milk C, wherein the density of the concentrated milk C is 1100-1150kg/m3；
S4, pumping the concentrated milk C into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 170-;
s5, adding arachidonic acid powder, fish oil powder, lactoferrin, osteopontin, nucleotide, lactobacillus paracasei N1115 and ganglioside into the material D, and mixing uniformly to obtain the infant formula milk powder for enhancing immunity.
TABLE 1 examples 1-6 raw materials for infant formula milk powder for boosting immunity
The content of lactobacillus paracasei N1115 in examples 1-6 was in order: 2X 1011 CFU/g、1×1011 CFU/g、3×1011 CFU/g、1×1012 CFU/g、6×1011 CFU/g、8×1011CFU/g. The multivitamins of examples 1-6 contain the following components: vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, vitamin C, biotin, and pantothenic acid; the compound mineral comprises the following components: sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium.
TABLE 2 Process parameters for examples 1-6
Example 7 in vitro cell model evaluation
In this example, different Lactoferrin (LF) and Osteopontin (OPN) addition ratios are set for the composite lactobacillus paracasei N1115, and the dominance ratios of the ingredients are evaluated by an in vitro cell model, specifically the evaluation method is as follows:
caco-2 cells were cultured for 2 hours in a serum-free medium, and then incubated for 72 hours at 37 ℃ in a cell culture medium containing 1% fetal calf serum supplemented with Lactoferrin (LF), Osteopontin (OPN) and Lactobacillus paracasei N1115, respectively, and LF-OPN mixture at different concentration ratios combined with Lactobacillus paracasei N1115 (the specific addition concentration is shown in Table 3, diluted 20 times). The cell culture medium was collected, concentrated by an ultrafiltration centrifuge tube, and the content of IL-18 was measured using an ELISA kit.
TABLE 3 mixture composition
Referring to FIG. 1, it is shown that lactoferrin, osteopontin, and N1115 can promote secretion of IL-18 by Caco-2 cells in FIG. 1. The combination of the three components showed the best effect of promoting IL-18 secretion, and the best effect was obtained when LF: OPN =4: 1.
Example 8 testing of an Immunity-enhancing infant milk formula
In this example, 30 suckling mice are randomly divided into 2 groups, which are an experimental group and a control group, each group comprises 15 suckling mice, the infant formula milk powder for enhancing immunity in the experimental group of the gavage example 1, the common infant milk powder (without the addition of the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115, and the addition of other raw and auxiliary materials are the same as those in the example 1) with the same dose in the control group of the gavage, the test period is 14 days, the weight of the suckling mice is measured every 2 days, and the feces are taken for sIgA detection at 0 day, 7 days and 14 days, and the results are shown in fig. 2 and 3.
As can be seen from FIG. 2, the body weight of both the experimental group and the control group continuously increased with the time after birth, and at 7 days and 14 days, the body weight of the experimental group suckling mice was significantly higher than that of the control group suckling mice, and the growth rate of the experimental group suckling mice was significantly higher than that of the control group. Therefore, the infant formula added with the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115 can better promote the growth and development of mice.
As can be seen from the graph 3, the fecal sIgA concentration of the suckling mice in the control group and the experimental group shows a gradually rising trend along with the time extension, which indicates that the intestinal tracts of the two groups of mice are normally developed, and compared with the control group, the fecal sIgA concentration of the experimental group of suckling mice is obviously raised at 14 days, which indicates that the infant formula milk powder added with the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115 can promote the intestinal tract immunity and enhance the resistance.
Claims (8)
1. The infant formula milk powder for enhancing immunity is characterized by comprising, by weight, 60-75 parts of cow milk, 8-12 parts of lactose, 5-8 parts of partially-enzymolyzed desalted whey powder, 3-6 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 2-4 parts of soybean oil, 1-3 parts of concentrated whey protein powder, 1-3 parts of linseed oil, 0.5-1.5 parts of galactose, 0.4-1 part of anhydrous cream, 0.1-0.5 part of fructo-oligosaccharide, 0.1-0.3 part of phospholipid, 0.1-0.3 part of arachidonic acid powder, 0.1-0.3 part of compound mineral substance, 0.1-0.2 part of fish oil powder, 0.1-0.2 part of compound vitamin, 0.1-0.2 part of lactoferrin, 0.05-0.1 part of calcium carbonate, 0.1 part of calcium carbonate, 0.025-0.05 part of osteopontin, 0.01-0.05 part of potassium hydroxide, 0.01-0.05 part of choline chloride, 0.01-0.05 part of nucleotide and 0.01-0.05 part of lactobacillus paracasei N1115.
2. The infant formula milk powder for improving immunity according to claim 1, wherein the raw material composition for preparing the effective components further comprises 0.005-0.01 parts by weight of ganglioside.
3. The enhanced immunity infant formula milk powder according to claim 1 or 2, wherein the partially enzymatically hydrolyzed desalted whey powder has an enzymatic hydrolysis degree of 10%.
4. The enhanced immunity infant formula milk powder of claim 1 or 2 wherein the lactobacillus paracasei N1115 is present in an amount of 1 x 1011-1×1012 CFU/g。
5. The enhanced immunity infant formula of claim 3The milk powder is characterized in that the content of lactobacillus paracasei N1115 is 1 multiplied by 1011-1×1012 CFU/g。
6. The infant formula milk powder for improving immunity according to any one of claims 1, 2 and 5, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the active ingredients is 4:1 in parts by weight.
7. The infant formula milk powder for improving immunity according to claim 3, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the effective ingredients is 4:1 in parts by weight.
8. The infant formula milk powder for improving immunity according to claim 4, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the effective ingredients is 4:1 in parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011064571.3A CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011064571.3A CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112075504A true CN112075504A (en) | 2020-12-15 |
Family
ID=73730890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011064571.3A Withdrawn CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112075504A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068591A (en) * | 2022-07-06 | 2022-09-20 | 合生元（广州）健康产品有限公司 | Probiotic composition containing osteopontin |
| CN115989871A (en) * | 2021-10-20 | 2023-04-21 | 安琪纽特股份有限公司 | Composition for promoting growth and development as well as preparation method and application thereof |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
-
2020
- 2020-09-30 CN CN202011064571.3A patent/CN112075504A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115989871A (en) * | 2021-10-20 | 2023-04-21 | 安琪纽特股份有限公司 | Composition for promoting growth and development as well as preparation method and application thereof |
| CN115068591A (en) * | 2022-07-06 | 2022-09-20 | 合生元（广州）健康产品有限公司 | Probiotic composition containing osteopontin |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112075504A (en) | Infant formula milk powder for enhancing immunity | |
| CN1838888A (en) | Infant or follow-on formula | |
| CN110179121A (en) | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application | |
| CN110506793A (en) | Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof | |
| CN107594279A (en) | A kind of probiotic powder solid beverage and preparation method thereof | |
| RU2600877C2 (en) | Fermented infant formula | |
| CN104381681A (en) | Antibiotic-free pig creep conservation general concentrate and complete feed thereof | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN112535218A (en) | Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof | |
| CN104717890A (en) | Fermented infant formula with non digestible oligosaccharides | |
| CN112167360A (en) | Low-sensitization infant formula goat milk powder | |
| CN112790250A (en) | Infant formula milk powder for promoting intestinal health and preparation method thereof | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| CN114223729B (en) | Application of bifidobacterium longum subspecies infantis and breast milk oligosaccharide composition in formula milk powder | |
| CN107668208A (en) | A kind of formula milk for promoting intestinal health | |
| CN110122865A (en) | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide | |
| CN110692741A (en) | Formula milk powder for promoting bone growth and preparation method thereof | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN112167348A (en) | Formula milk powder for promoting growth and development of children and preparation method thereof | |
| CN108669563A (en) | A kind of composition, its application and strengthen immunity, the product for improving allergy | |
| CN110200186B (en) | Probiotic solid beverage and preparation method thereof | |
| CN112535217A (en) | Maternal emulsified hypoallergenic fresh and alive infant formula milk and preparation method thereof | |
| CN107897380A (en) | A kind of close to breast milk and have the function of prebiotic babies ' formula milk powder of enteron aisle and preparation method thereof | |
| CN111972497A (en) | Children formula milk powder capable of improving immunity and constipation and preparation method thereof | |
| CN115053929B (en) | Formula milk powder suitable for fatty liver people and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201215 |
|
| WW01 | Invention patent application withdrawn after publication |